#USA #Cleveland #Neuromodulation #Neuronoff #Injectrode

Neuronoff's Innovative Injectrode® Platform

Neuronoff, Inc., a trailblazer in clinical-stage neuromodulation, recently announced a remarkable breakthrough with its Injectrode® platform. This pioneering technology allows for multi-site compatibility with Implantable Pulse Generators (IPGs), a development that could revolutionize neuromodulation treatment modalities beyond traditional spinal cord stimulation.

Significant Breakthrough in Neuromodulation

At a recent demonstration involving large animal studies, Neuronoff showcased its ability to selectively stimulate multiple anatomical neural targets. This cutting-edge system connects tripolar electrodes, delivered via a slim 1.5mm needle, to standard IPGs using Bal Seal connectors, demonstrating the potential for chronic stimulation of the Lumbar Dorsal Root Ganglion (DRG), peripheral nerves, and sacral regions.

The experiments revealed that physicians could access various nerve targets—an exciting prospect that expands the scope of treatable nerve conditions previously restricted to surgical interventions. An example cited by Neuronoff's CEO, Manfred Franke, emphasized how this technology opens up an entire market of peripheral nerve stimulation procedures that have been traditionally underserved.

Overcoming Surgical Barriers

Historically, targeting peripheral nerves required extensive surgical procedures, which posed considerable risks and recovery challenges. Neuronoff's Injectrode changes this narrative. By utilizing minimally invasive techniques and existing CPT reimbursement codes for peripheral nerve stimulation trials and treatments, it sidesteps the typical barriers hindering the adoption of innovative therapies.

Franke elaborated on the implications of such a shift, remarking, "Spinal cord stimulation has been the primary market for IPGs for decades, but there are numerous nerve targets that can be accessed simply and effectively now. This is a fundamentally different market landscape."

The Path to Commercialization

Looking ahead, Neuronoff aims to file for FDA submissions in mid-2026, focusing on their externally powered Injectrode system. The potential for these systems to connect seamlessly with traditional IPGs to facilitate a patient’s journey from initial trial to long-term therapy appears increasingly viable. According to the company, patients will enjoy the benefits of neuromodulation therapies without needing invasive surgeries and with reduced procedural times compared to current approaches.

The Injectrode platform is a versatile neuromodulation solution that caters to a wide array of indications including pain management, bladder control, cardiac-related issues, and inflammation treatments—all without opioids or surgical intervention.

Conclusion

Neuronoff's progress marks a significant milestone in the neuromodulation sector, offering both clinicians and patients a less invasive, more accessible method of pain management. As they prepare for commercialization, their innovative strategy and focus on minimally invasive treatment options may very well redefine the landscape of neuromodulation therapies and the broader market for IPGs. The implications of this technology could not only assist in pain relief but fundamentally alter the approach to treating neuromodulation conditions, suggesting a future where surgical complexities are rendered unnecessary.